BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 35278260)

  • 1. Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients.
    Salerno DM; Jennings DL; Lange NW; Kovac DB; Shertel T; Chen JK; Hedvat J; Scheffert J; Brown RS; Pereira MR
    Am J Transplant; 2022 Aug; 22(8):2083-2088. PubMed ID: 35278260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the use of nirmatrelvir/ritonavir in solid organ transplant recipients with COVID-19: A review of immunosuppressant adjustment strategies.
    Tang Y; Li Y; Song T
    Front Immunol; 2023; 14():1150341. PubMed ID: 37081880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-drug interactions of ritonavir-boosted SARS-CoV-2 protease inhibitors in solid organ transplant recipients: experience from the initial use of lopinavir-ritonavir.
    Gonzalez-García R; Roma JR; Rodríguez-García M; Arranz N; Ambrosioni J; Bodro M; Castel MÁ; Cofan F; Crespo G; Diekmann F; Farrero M; Forner A; LLigoña A; Marcos MÁ; Moreno A; Ruiz P; Soy D; Brunet M; Miró JM; Tuset M
    Clin Microbiol Infect; 2023 May; 29(5):655.e1-655.e4. PubMed ID: 36641051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of nirmatrelvir/ritonavir on calcineurin inhibitor levels: Early experience in four SARS-CoV-2 infected kidney transplant recipients.
    Wang AX; Koff A; Hao D; Tuznik NM; Huang Y
    Am J Transplant; 2022 Aug; 22(8):2117-2119. PubMed ID: 35158412
    [No Abstract]   [Full Text] [Related]  

  • 5. "Saving lives with nirmatrelvir/ritonavir one transplant patient at a time".
    Belden KA; Yeager S; Schulte J; Cantarin MPM; Moss S; Royer T; Coppock D
    Transpl Infect Dis; 2023 Apr; 25(2):e14037. PubMed ID: 36847419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series.
    Guzmán Cordero C; Saez-Torres de Vicente M
    Eur J Hosp Pharm; 2024 Feb; 31(2):175-177. PubMed ID: 36535689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients - a case series with four patients.
    Schneider J; Wobser R; Kühn W; Wagner D; Tanriver Y; Walz G
    BMC Nephrol; 2023 Apr; 24(1):99. PubMed ID: 37061677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nirmatrelvir/ritonavir Use With Tacrolimus in Lung Transplant Recipients: A Single-center Case Series.
    Dewey KW; Yen B; Lazo J; Seijo L; Jariwala R; Shah RJ; Quan D; Carpenter B; Paul Singer J; Breen K; Hays S; Florez R
    Transplantation; 2023 May; 107(5):1200-1205. PubMed ID: 36525555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report.
    Prikis M; Cameron A
    Transplant Proc; 2022; 54(6):1557-1560. PubMed ID: 35599203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenytoin enzyme induction for management of supratherapeutic tacrolimus levels due to drug-drug interaction with nirmatrelvir/ritonavir: Case series and discussion.
    Marsh J; Logan AT; Bilgili EP; Bowman LJ; Webb AR
    Am J Health Syst Pharm; 2024 Jun; 81(13):e345-e352. PubMed ID: 38347740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome in heart transplant recipients receiving everolimus in combination with dosage reduction of the calcineurin inhibitor cyclosporine A or tacrolimus.
    Fuchs U; Zittermann A; Ensminger SM; Schulz U; Gummert JF
    Transpl Immunol; 2014 Aug; 31(2):87-91. PubMed ID: 24932812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.
    Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Rådegran G; Gude E; Jansson K; Solbu D; Karason K; Arora S; Dellgren G; Gullestad L;
    Am J Transplant; 2016 Apr; 16(4):1238-47. PubMed ID: 26820618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era.
    Hedvat J; Lange NW; Salerno DM; DeFilippis EM; Kovac D; Corbo H; Chen JK; Choe JY; Lee JH; Anamisis A; Jennings DL; Codispodo G; Shertel T; Brown RS; Pereira MR
    Am J Transplant; 2022 Nov; 22(11):2682-2688. PubMed ID: 35801839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nirmatrelvir-ritonavir for COVID-19.
    McDonald EG; Lee TC
    CMAJ; 2022 Feb; 194(6):E218. PubMed ID: 35115376
    [No Abstract]   [Full Text] [Related]  

  • 17. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
    Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
    BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Recipients: One-Year Results of a Scandinavian Randomized Trial.
    Arora S; Andreassen AK; Andersson B; Gustafsson F; Eiskjaer H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Sigurdardottir V; Dellgren G; Erikstad I; Solberg OG; Ueland T; Aukrust P; Gullestad L;
    Am J Transplant; 2015 Jul; 15(7):1967-75. PubMed ID: 25783974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study.
    Ganschow R; Ericzon BG; Dhawan A; Sharif K; Martzloff ED; Rauer B; Ng J; Lopez P
    Pediatr Transplant; 2017 Nov; 21(7):. PubMed ID: 28714558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, Efficacy, and Relapse of Nirmatrelvir-Ritonavir in Kidney Transplant Recipients Infected With SARS-CoV-2.
    Devresse A; Sébastien Briol ; De Greef J; Lemaitre F; Boland L; Haufroid V; Scohy A; Kabamba B; Yombi JC; Belkhir L; Darius T; Buemi A; De Potter K; Mantegazza R; Bearzatto B; Goffin E; Kanaan N
    Kidney Int Rep; 2022 Nov; 7(11):2356-2363. PubMed ID: 36060621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.